Huber Capital Management LLC Increases Stake in Pfizer Inc. (NYSE:PFE)

Huber Capital Management LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 142.4% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 488,288 shares of the biopharmaceutical company's stock after buying an additional 286,842 shares during the quarter. Pfizer accounts for 2.6% of Huber Capital Management LLC's investment portfolio, making the stock its 13th largest holding. Huber Capital Management LLC's holdings in Pfizer were worth $12,954,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also bought and sold shares of the stock. Nordea Investment Management AB raised its stake in shares of Pfizer by 36.1% during the 4th quarter. Nordea Investment Management AB now owns 4,071,700 shares of the biopharmaceutical company's stock worth $108,002,000 after purchasing an additional 1,080,822 shares during the period. Parsons Capital Management Inc. RI increased its stake in shares of Pfizer by 118.7% during the 4th quarter. Parsons Capital Management Inc. RI now owns 294,764 shares of the biopharmaceutical company's stock worth $7,820,000 after purchasing an additional 159,984 shares during the last quarter. Copley Financial Group Inc. bought a new stake in shares of Pfizer in the 3rd quarter worth approximately $577,000. Zacks Investment Management lifted its stake in Pfizer by 10.9% in the third quarter. Zacks Investment Management now owns 2,389,138 shares of the biopharmaceutical company's stock valued at $69,142,000 after purchasing an additional 235,243 shares during the last quarter. Finally, Geode Capital Management LLC grew its holdings in Pfizer by 1.6% during the third quarter. Geode Capital Management LLC now owns 117,666,245 shares of the biopharmaceutical company's stock valued at $3,392,342,000 after purchasing an additional 1,855,419 shares during the period. 68.36% of the stock is currently owned by institutional investors.

Remove Ads

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on PFE. Truist Financial cut their price target on Pfizer from $36.00 to $32.00 and set a "buy" rating for the company in a research note on Wednesday, December 18th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research note on Tuesday, March 18th. Bank of America restated a "neutral" rating and set a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a report on Thursday, March 27th. Finally, UBS Group lowered their target price on shares of Pfizer from $31.00 to $29.00 and set a "neutral" rating on the stock in a report on Wednesday, January 8th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating, six have given a buy rating and three have issued a strong buy rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and an average price target of $31.92.

Insider Buying and Selling at Pfizer

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the business's stock in a transaction dated Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.06% of the stock is currently owned by corporate insiders.

Pfizer Trading Down 1.6 %

Shares of NYSE:PFE traded down $0.41 on Thursday, reaching $24.30. 53,412,700 shares of the company traded hands, compared to its average volume of 39,310,365. The business's 50-day simple moving average is $25.93 and its 200 day simple moving average is $26.81. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. Pfizer Inc. has a 52 week low of $24.26 and a 52 week high of $31.54. The stock has a market capitalization of $137.79 billion, a P/E ratio of 17.23, a price-to-earnings-growth ratio of 0.64 and a beta of 0.61.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion for the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm's revenue for the quarter was up 24.7% on a year-over-year basis. During the same period in the previous year, the firm earned $0.10 earnings per share. As a group, equities analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.